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Abstract
Objective: Search and review of available literature were made to define the indications for and timing
of liver transplantation for neuroendocrine tumour (NET) liver metastases.
Methods: Electronic bibliographical databases were searched. Prospective and retrospective cohort
studies and case–controlled studies were used for qualitative and quantitative synthesis of the systematic
review. Reports of patients with liver transplantation alone for NET liver metastases of any origin or
combined with resection of extrahepatic tumour deposits were recruited.
Results: The number of patients who have undergone liver transplantation for NET liver metastases is
706. The post-transplant 5-year survival rate from the time of diagnosis was approximately 70%. NET
patients with metastases confined to the liver and not poorly differentiated are favourable candidates
for liver transplantation. Selection of patients based on evolution of tumours over 6 months is not
recommended.
Conclusion: Non-resectable NET liver metastasis resistant to medical treatment and confined to the
liver is an accepted indication for liver transplantation.
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Introduction
Neuroendocrine tumour (NET) metastasis localized to the liver is
an accepted indication for liver transplantation as such tumours
have a low biological aggressiveness in terms of malignancy and are
slow growing. Moreover, the long-term results are comparable with
and in some cases even better than those of transplantations per-
formed for primary liver cancer.1 However, compared with non-
malignant conditions, NET liver metastasis may result in an
inferior outcome of transplantation.2 In the face of the scarcity
of donated organs and recent improved results of non-surgical
treatment for NET liver metastases, controversy over patient selec-
tion and timing for liver transplantation continues. A systematic
review of the recent literature was made to answer the following
questions:
1 In patients with non-resectable NET liver metastases, does
liver transplantation improve the outcome as opposed to R2
liver resection (debulking) or non-surgical treatment?
2 In patients with NET liver metastases, which selection criteria
should be used for liver transplantation in order to improve
the outcome (disease-free survival, overall survival, quality of
life)?
3 In patients with NET liver metastases and consideration for liver
transplantation, does a delay (>6 months) to assess tumour
progression before transplantation improve the selection of
patients as opposed to early transplantation (<6 months)?
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4 In patients with NET liver metastases listed for transplantation,
do downstaging techniques (locally ablative techniques, percu-
taneous liver-directed techniques, peptide receptor radionuclide
treatment, chemotherapy, target therapy and biotherapy)
improve the post-transplant outcome?
5 In patients with non-resectable NET liver metastases, does living
donor liver transplantation (LDLT) improve the outcome as
opposed to deceased donor liver transplantation (DDLT) or
non-surgical treatment?
6 Does the outcome of the recipient justify the risk of the
donor in the setting of liver transplantation for NET liver
metastases?
Methods
Searches
The following electronic bibliographic databases were searched:
MEDLINE, EMBASE and the Cochrane Library [Cochrane
Database of Systematic Reviews, Database of Abstracts of
Reviews of Effects, and Central Register of Controlled Trials
(CENTRAL)].3
Types of study included
Prospective and retrospective comparative cohort studies and
case-controlled studies were used for the qualitative and quanti-
tative synthesis of the systematic review. Patient series were
included in a separate database for descriptive purposes. Single
patient reports were not included. The review protocol was pub-
lished by Stump et al.3
Patient population
The patient population included in this analysis was composed
of (i) patients with non-resectable NET liver metastases of any
origin, patients who underwent liver transplantation or pallia-
tive liver resection or non-surgical treatment, (ii) patients with
pre-operative/intra-operative diagnosis of primary tumours and
lymph node secondaries and (iii) patients with liver transplanta-
tion combined with surgical resection of extrahepatic tumour
deposits.
Exclusion criteria
Patients under the age of 18 years and studies that did not report
overall survival were excluded.
Comparator/control
Liver transplantation versus palliative liver resection versus non-
surgical treatment.
Outcomes
Primary outcome: overall survival
Secondary outcome: disease-free survival
Results
The literature search resulted in 46 relevant publications on liver
transplantation for NET liver metastasis (Fig. 1). A total of 873
patients were reported in these publications. Excluding obvious
overlaps or duplications, the number of liver transplantations for
NET liver metastases was 706. The reported 5-year overall survival
rates in the different series varied from 0% to 100%. Disease-free
survival was not routinely reported but the reported 5-year
disease-free survival rates varied from 0 to 80%. Most reports
described frequent and early recurrences of NET after liver trans-
plantation. The wide ranges of survival rates reflect the small
number of patients in each report, short duration of follow-up
and significant selection bias. In series with more than 100
patients,1,4 the average 5-year overall survival rate and disease-free
survival rate were about 50% and 30%, respectively (Table 1).
There was no study that addressed the quality of life after liver
transplantation.
Table 1 NET liver metastases and liver transplantation: recurrence and survival rates
Rosenau
et al.
(2002)12
van
Vilsteren
et al.
(2006)14
Olausson
et al.
(2007)13
Le Treut
et al.
(2008)7
Frilling
et al.
(2009)5
Mazzaferro
et al.
(2010)16
Gedaly
et al.
(2011)1
Nguyen
et al.
(2011)4
Le Treut
et al.
(2013)8
Number of patients 19 19 15 85 15 24 150 184 213
5-year post-transplant
survival
80% NR 90% 47% 67.2% 90% 49% 49.2% 52%
5-year post-transplant
disease-free survival
22% NR 18% 20% 48.3% 77% 32% NR 30%
Number of patients
surviving without disease
3 16 4 NR 5 NR NR NR 63
5-year survival after
diagnosis of liver
metastasis
NR NR NR 69% NR NR NR NR 73%
NR, Not reported.
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Response to Question 1
There was no prospective randomized trial to show the supe-
riority of liver transplantation over resection or non-surgical
treatment. In the very few comparative studies5,6 that included
resection or non-surgical treatment as a control, the overall 5-year
survival of transplanted patients was about the same as non-
transplanted patients, but the rate of 5-year disease-free survival
was higher for transplanted patients (50% versus 34%) (Table 1).
As liver transplantation is often performed after all other treat-
ment modalities have been exhausted, evaluation of outcome
using post-transplant survival duration may not be valid when
liver transplantation is compared with non-transplant treatment.
A better measurement would be duration of survival after diag-
nosis of liver metastases. The rate of 5-year survival after diagnosis
of liver metastases was 69–84% for patients who received trans-
plantation,7,8 34% for patients who underwent non-surgical treat-
ment,5,6 and 20–30% for patients not treated.9,10 An alternative
measurement would be survival from the time of uncontrolled
tumour progression because transplantation is frequently
performed when the tumour is observed growing
at a faster pace. However, such survival data were not available
in the reports. Because of the highly selective nature of patients
chosen for non-surgical treatment, resection or transplantation,
randomized controlled trials evaluating patient outcomes with
these treatment modalities would be difficult to perform.
Response to Question 2
Patients with NET liver metastases were frequently subjected to
liver transplantation when surgical or non-surgical treatment
failed to control the tumours. The risk factors for recurrence or
inferior survival derived from experiences at major centres were:
age over 50 years, a symptomatic tumour, a primary tumour in the
pancreas or a non-gastrointestinal location, a non-carcinoid
tumour, a high Ki-67 index, involvement of liver >50% and poor
tumour differentiation.1,4–7,11–15 Multivisceral transplantation and
additional major resection were found to have adverse effects on
long-term outcome.8,13 Thus, extrahepatic spread and a primary
tumour not resected (necessitating an additional procedure or
graft) are to be considered definite contraindications to liver
transplantation. However, the majority of the adverse risk factors
have not been validated in prospective studies. Moreover, the risk
factors were not all derived from multivariate analysis (Table 2).
Based on multivariate analysis of the data of 213 patients in the
European Liver Transplant Registry, the significant risk factors
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1139 records after duplicates removed
1139 records screened 1065 records excluded
1637 records identified through
database searching
0 additional records identified
through other soures
74 full-text articles
assessed for eligibility
28 full-text articles
excluded, with reasons
0 studies included in
qualitative synthesis
46 studies included in
quantitative synthesis
(meta-analysis)
Figure 1 Flow diagram demonstrating retrieval of reports of neuroendocrine tumour liver-metastases from the literature
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were multivisceral resections or multivisceral grafts, a poorly
differentiated tumour and hepatomegaly as a surrogate of
intrahepatic tumour burden.8 If patients without such risk factors
are selected, the rate of 5-year survival can reach 60–80%.8
In summary, liver transplantation is suitable for patients with
disease burden confined to the liver. Patients with well-
differentiated tumours appeared to be the best candidates for liver
transplantation.
Response to Question 3
In a study by Mazzaferro et al., a delay (>6 months) to assess
tumour progression before transplantation was arbitrarily chosen
as an inclusion criterion, and remarkable transplant results were
produced.16 However, the cause-to-effect relationship between
this criterion and the results was not proven as there were many
other stringent selection parameters in the criteria adopted by
them. It is possible to assume that NET liver metastasis having
evolved over a long time would have a better outcome after liver
transplantation (Fig. 2). This hypothesis has found confirmation
in retrospective data on transplantation for NET.1 Currently, many
physicians have the perception that asymptomatic patients with
stable diseases may not require liver transplantation whereas
patients with progressive diseases refractory to non-surgical treat-
ment may require liver transplantation. The available evidence
does not permit any strong conclusion. Further prospective
studies are needed before ‘disease with a stable period of 6 months’
can be established as an important criterion in the selection.
Response to Question 4
There are scarce data on the improvement of outcome of liver
transplantation for NET liver metastases by downstaging of
disease. Analysis of the 35 000 patients in the Surveillance, Epide-
miology and End Results (SEER) database demonstrated that
the use of somatostatin analogues correlates with survival
Table 2 NET liver metastases and liver transplantation: risk factors for recurrence and survival
Rosenau
et al. (2002)12
van
Vilsteren
et al.
(2006)14
Olausson
et al.
(2007)13
Le Treut
et al.
(2008)7
Frilling
et al.
(2009)5
Mazzaferro
et al.
(2010)16
Gedaly
et al.
(2011)1
Nguyen
et al.
(2011)4
Le Treut
et al.
(2013)8
Age over 50 years No No No No No Yes No No Yes
Symptomatic tumour No No No No No Yes NR NR NR
Primary tumour in the
pancreas
No No No Yes NR Yes NR NR Yes
Non-carcinoid tumour No No NR No NR Yes No NR NR
Primary tumour at
non-portal drainage site
No NR No NR NR Yes NR NR NR
Ki-67 index (%) or aberrant
E-cadherin
Yes No Yes >10 NR Yes >10 Yes >5 NR NR NR
Liver involvement >50% of
standard liver volume or
hepatomegaly
NR NR No Yes No Yes NR NR Yes
Extrahepatic spread Yes NR Yes Yes Yes Yes No No Yes
Primary tumour not
resected
Yes NR Yes Yes Yes Yes No No Yes
Stable period (months) NR Yes <6 NR NR Yes <6 Yes <6 Yes <2 Yes NR
Multivisceral transplant or
additional major resection
Yes NR Yes Yes Yes Yes No No Yes
Histology (poor
differentiation)
NR No NR Yes Yes NR NR NR Yes
NET, neuroendocrine tumour; NR, Not reported.
Figure 2 Benefit of liver transplantation for neuroendocrine tumour
(NET) metastases in liver
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benefit.17 It is expected that a similar benefit should be observed
in a pre-transplant setting. However, data are not available. Prop-
erly designed studies would address the issue of the possible
ameliorating effect of downstaging therapies on prolonging the
time to progression of tumours and hence delaying the need for
transplantation.
Response to Question 5
There are only 21 reported LDLTs for NET liver metasta-
ses.1,11,14,15,18 No separate analysis of the efficacy of LDLT versus
DDLT was done in these reports. It is therefore impossible to
identify any advantage of LDLT over DDLT or vice versa. As
patients with NET liver metastases may not have access to
deceased donor organs owing to organ allocation regulations,
LDLT may be their only hope of a cure. However, as the long-term
results of LDLT for NET liver metastases are not known, criteria
for selection of patients for LDLT should not differ from those for
DDLT. Further studies are needed to document the advantages of
LDLT over DDLT, if any.
Response to Question 6
The outcome of LDLT for NET liver metastases is not known
exactly. Assuming the 5-year overall survival rate of LDLT for NET
liver metastases is similar to that of DDLT or that for hepatocel-
lular carcinoma (60%), it seems that such an outcome can justify
the 0.1–0.5% mortality risk posed to donors.19
Summary
• In carefully selected patients, non-resectable NET liver metas-
tasis resistant to medical treatment is an accepted indication for
liver transplantation. (Recommendation: Strong)
• NET patients with metastases confined to the liver and not
poorly differentiated are favourable candidates for liver trans-
plantation. (Recommendation: Strong)
• The selection of patients with NET liver metastases based on
evolution of tumour over 6 months is still controversial. The
available evidence does not allow any conclusion. (Recommen-
dation: Weak)
• Balancing the survival rate of NET liver metastases patients after
transplantation with the donor risk, LDLT may be justified. The
criteria for selection of patients with NET liver metastases for
LDLT should not differ from those for DDLT.(Recommendation:
Weak)
Future perspectives
As liver transplantation is uncommonly performed for NET
liver metastases and data are scarce, a strong recommendation
for most of the concerns of liver transplantation cannot be made
at the present time. Documentation of benefits of liver trans-
plantation for NET liver metastases is likely in a subgroup of
patients. However, this would require detailed and prospec-
tive collection of clinical, radiological and biological data. A
worldwide registry of liver transplantations for NET liver metas-
tases is needed.
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